| scholarly article | Q13442814 |
| P50 | author | Ralph Weissleder | Q7288259 |
| P2093 | author name string | Xianghui Ren | |
| Marie Classon | |||
| Khalid Shah | |||
| Shawn Hingtgen | |||
| Ernie Terwilliger | |||
| P2860 | cites work | Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL | Q24554360 |
| Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy | Q28176737 | ||
| APO2 ligand: a novel lethal weapon against malignant glioma? | Q28272697 | ||
| The leading edge of stem cell therapeutics | Q28273636 | ||
| Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials | Q30686073 | ||
| Brain tumor survival: results from the National Cancer Data Base | Q31932199 | ||
| mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells | Q34097241 | ||
| Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials | Q34429383 | ||
| Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells | Q34618860 | ||
| Chemoradiotherapy in malignant glioma: standard of care and future directions | Q34683223 | ||
| Gene therapy for human malignant brain tumors. | Q35210470 | ||
| Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. | Q35812718 | ||
| Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy | Q36112074 | ||
| Molecular optical imaging: applications leading to the development of present day therapeutics | Q36129726 | ||
| Current advances in molecular imaging of gene and cell therapy for cancer | Q36134770 | ||
| Adeno-associated virus vectors: potential applications for cancer gene therapy | Q36165834 | ||
| Genetic strategies for brain tumor therapy | Q36247099 | ||
| TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer | Q36365504 | ||
| Treatment of human disease by adeno-associated viral gene transfer | Q36448393 | ||
| Adjuvant treatment of high grade gliomas. | Q36612677 | ||
| Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway | Q36649992 | ||
| The promise of TRAIL--potential and risks of a novel anticancer therapy | Q36792997 | ||
| Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model | Q39988659 | ||
| MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas | Q40073679 | ||
| Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand | Q40114772 | ||
| Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma | Q40261023 | ||
| Criteria for analyzing interactions between biologically active agents | Q40328980 | ||
| A combination of mutations enhances the neurotropism of AAV-2. | Q40384910 | ||
| Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines | Q40432328 | ||
| Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. | Q40476541 | ||
| Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model | Q40508031 | ||
| Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis | Q40860890 | ||
| Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression | Q42835214 | ||
| Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells | Q43513023 | ||
| Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene | Q43624125 | ||
| CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release | Q43682296 | ||
| Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. | Q43713225 | ||
| Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy | Q44198636 | ||
| Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo | Q44611172 | ||
| DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system | Q45025213 | ||
| Motor and cognitive improvements in patients with Huntington's disease after neural transplantation | Q45301920 | ||
| Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. | Q45735544 | ||
| Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration | Q45864572 | ||
| Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand | Q46324484 | ||
| Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety | Q46661382 | ||
| Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine | Q48479768 | ||
| In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. | Q55471304 | ||
| Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. | Q55476497 | ||
| Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene | Q64379934 | ||
| P433 | issue | 11 | |
| P921 | main subject | temozolomide | Q425088 |
| P304 | page(s) | 3575-3585 | |
| P577 | publication date | 2008-11-01 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide | |
| P478 | volume | 7 |
| Q34341900 | A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy |
| Q39744489 | A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. |
| Q34384021 | Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer |
| Q37483966 | Applications of neural and mesenchymal stem cells in the treatment of gliomas |
| Q60935363 | Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma |
| Q36936884 | Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma. |
| Q38960128 | Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors |
| Q38230650 | Current evidence of temozolomide and bevacizumab in treatment of gliomas. |
| Q35048739 | Effect of temozolomide on livin and caspase-3 in U251 glioma stem cells |
| Q30843565 | Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma |
| Q36695971 | Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas |
| Q34474267 | Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas |
| Q99207673 | Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients |
| Q36684365 | Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer. |
| Q33828114 | Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. |
| Q35673628 | Gene therapy for malignant glioma |
| Q94660275 | Generation and Profiling of Tumor-Homing Induced Neural Stem Cells from the Skin of Cancer Patients |
| Q34310698 | Gliomagenesis and the use of neural stem cells in brain tumor treatment |
| Q42577813 | Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme |
| Q57640952 | Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection |
| Q41084396 | KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL. |
| Q35419466 | Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway |
| Q39649349 | Lentiviral transfer of an inducible transgene expressing a soluble form of Gas1 causes glioma cell arrest, apoptosis and inhibits tumor growth |
| Q33704489 | Neural stem cell therapy for cancer |
| Q37585453 | Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma |
| Q37641600 | Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide |
| Q36913828 | Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors |
| Q37049935 | Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme. |
| Q42494301 | Regulating the expression of therapeutic transgenes by controlled intake of dietary essential amino acids |
| Q37403279 | Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity |
| Q37818222 | Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma |
| Q34240433 | Stem cells as therapeutic vehicles for the treatment of high-grade gliomas |
| Q37420576 | Strategies in gene therapy for glioblastoma. |
| Q26850467 | Sui generis: gene therapy and delivery systems for the treatment of glioblastoma |
| Q36500367 | TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo |
| Q38730195 | Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors |
| Q42479312 | Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein |
| Q61797351 | The pro-apoptotic Bcl-2 family member Harakiri (HRK) induces cell death in glioblastoma multiforme |
| Q27333831 | Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma. |
| Q48329121 | Tumor-homing cytotoxic human induced neural stem cells for cancer therapy. |
| Q37567452 | Viruses, gene therapy and stem cells for the treatment of human glioma. |
Search more.